Managed Entry Agreements as a strategy for introducing new high cost medicines

The purpose of this study is to explore the value of MEA implementation to different stakeholders in an international context and to assess whether there could be a growing support among stakeholders for MEAs in Norway. Managed Entry Agreements contain an arrangement between a [pharmaceutical] manufacturer and a payer/provider that enables access to a health technology subject to specific conditions. Assessment of attitudes towards MEAs will include interviews with different stakeholders.

This is a masters degree project under the program called European Master in Health Economics and Management

TSD

  • Ja

Biobank

  • Nei

Godkjenninger

Prosjektet har ingen godkjenninger

Prosjektleder / prosjektansvarlig ved UiO

Oddvar Martin Kaarbøe

Ansvarlig enhet

Avdeling for helseledelse og helseøkonomi

Forskere

  • Peter Marjolein

Prosjekttype

  • Studentprosjekt – Bachelor-, master- eller spesialistoppgave

Helsefaglig forskning

  • Ja

Personopplysninger

  • Ikke besvart

Tidsperiode

  • Start: mai 2017
  • Slutt: november 2017